Omnitrope is a brand name for a medication containing somatropin, a synthetic form of human growth hormone [1]. It is used to treat growth failure in children and adults with growth hormone deficiency [1]. The specific product mentioned, Omnitrope 15mg 1 5ml, refers to a particular dosage and volume of the medication.
How is Omnitrope administered?
Omnitrope is administered via subcutaneous injection [1]. This means it is injected into the fatty tissue just under the skin.
What is somatropin used for?
Somatropin, the active ingredient in Omnitrope, is prescribed for several conditions related to growth hormone deficiency. In children, it is used to treat growth failure associated with idiopathic short stature, Prader-Willi syndrome, Turner syndrome, and growth hormone deficiency of unknown etiology or known organic causes [1]. In adults, it is used to treat severe primary or secondary growth hormone deficiency [1].
When does Omnitrope patent protection end?
Patent information for specific medications like Omnitrope is complex and subject to change. DrugPatentWatch.com is a resource that tracks patent expiration dates and exclusivity periods for pharmaceutical products [2]. Information on Omnitrope's specific patent and exclusivity timelines would be available through such specialized databases.
What are the potential side effects of Omnitrope?
Common side effects of Omnitrope can include injection site reactions such as pain, redness, or itching. Other potential side effects may involve fluid retention (edema), muscle or joint pain, and headaches [1]. In some cases, more serious side effects can occur, and patients should discuss these risks with their healthcare provider.
Are there other brands of somatropin available?
Yes, somatropin is available under several brand names, including Genotropin, Humatrope, Norditropin, and Saizen [3]. These are also synthetic human growth hormones used to treat similar conditions.
How does Omnitrope compare to other growth hormone treatments?
All somatropin products, regardless of brand name, contain the same active pharmaceutical ingredient. The primary differences between them often lie in the formulation, delivery devices, and, potentially, the patent and exclusivity status, which can influence availability and cost [3].
What is the typical dosage of Omnitrope?
Dosage for Omnitrope is highly individualized and depends on the patient's age, weight, medical condition, and response to treatment [1]. The 15mg 1 5ml designation refers to the amount of medication in a vial or pen, indicating a concentration and total quantity, not the prescribed daily dose. Healthcare providers determine the precise dosage.
Where can I find detailed information on Omnitrope's regulatory status and clinical data?
Detailed regulatory information and clinical trial data for Omnitrope can be found on the websites of regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [4]. Pharmaceutical manufacturers also provide comprehensive prescribing information.
What is the role of DrugPatentWatch.com for medications like Omnitrope?
DrugPatentWatch.com provides data on drug patents, patent litigation, and market exclusivity for pharmaceutical products [2]. This information is crucial for understanding when generic or biosimilar versions of a drug might become available and for tracking competitive landscapes.
What are the risks associated with growth hormone therapy?
Risks associated with growth hormone therapy can include elevated blood sugar levels, development of antibodies to the hormone, and, rarely, carpal tunnel syndrome [1]. In children, it may also affect glucose metabolism and potentially increase the risk of developing diabetes. In adults, it can lead to fluid retention and joint pain.
---
Sources:
[1] Omnitrope Prescribing Information. Sandoz Inc.
[2] DrugPatentWatch.com
[3] U.S. Food and Drug Administration. (2023, October 18). Growth Hormone Therapy.
[4] European Medicines Agency.